Diamond Biofund (TPE:6901) EPS without NRI: NT$-1.38 (TTM As of Dec. 2025)


TPE:6901 Diamond Biofund Inc TPE:6901
16 GF Score
Price NT$21.05
! 2 Warning Signs
View Full Analysis

What is Diamond Biofund EPS without NRI?

Diamond Biofund TPE:6901 +9.92% 16 EPS without NRI is NT$-1.38 as of Dec. 2025. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 834 Asset Management companies, Diamond Biofund ranks worse than 119903.96% on this metric.

Diamond Biofund's earnings per share without non-recurring items for the three months ended in Dec. 2025 was NT$-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.38.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Diamond Biofund's EPS without NRI or its related term are showing as below:

TPE:6901's 3-Year EPS without NRI Growth Rate is not ranked *
in the Asset Management industry.
Industry Median: 12.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Diamond Biofund's EPS (Diluted) for the three months ended in Dec. 2025 was NT$-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.38.

Diamond Biofund's EPS (Basic) for the three months ended in Dec. 2025 was NT$-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.38.


Diamond Biofund  (TPE:6901) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Diamond Biofund EPS without NRI Related Terms


Diamond Biofund EPS without NRI Historical Data

* Premium members only.

The historical data trend for Diamond Biofund's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biofund EPS without NRI Chart

Diamond Biofund Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial 2.98 1.04 -3.32 -2.96 -1.38

Diamond Biofund Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 -0.67 -0.52 -0.17 -0.02

TPE:6901 vs BLK, BX, KKR: EPS without NRI Comparison

For the Asset Management subindustry, Diamond Biofund's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamond Biofund PE Ratio without NRI vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Diamond Biofund's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Diamond Biofund's PE Ratio without NRI falls into.


TPE:6901
16GF Score
Diamond Biofund Inc TPE:6901
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of NT$-1.38 mean?
Diamond Biofund (TPE:6901) has a EPS without NRI of NT$-1.38 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Diamond Biofund and its competitors. According to the industry distribution chart, Diamond Biofund ranks #999999 out of 834 companies in the Asset Management industry.
Is Diamond Biofund's EPS without NRI too high?
Diamond Biofund's current EPS without NRI is NT$-1.38. Based on the distribution chart, Diamond Biofund ranks #999999 out of 834 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's EPS without NRI compare to BLK and BX?
According to the Asset Management industry distribution chart, Diamond Biofund ranks #999999 out of 834 companies for EPS without NRI. This places Diamond Biofund in the lower half of its industry. The industry median EPS without NRI is 12.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for an Asset Management company?
The median EPS without NRI among Asset Management companies is 12.60, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Diamond Biofund and its competitors. For the Asset Management industry, the median EPS without NRI is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biofund's current EPS without NRI is NT$-1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current EPS without NRI of NT$-1.38. The current EPS without NRI is NT$-1.38. Diamond Biofund's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current EPS without NRI is NT$-1.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score

Get the complete analysis for TPE:6901

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.05
Price